• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form N-PX filed by Johnson & Johnson

    8/26/25 4:27:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    Form N-PX Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM N-PX
    ANNUAL REPORT OF PROXY VOTING RECORD
    OMB APPROVAL


    Form N-PX

    OMB Number:  3235-0582


    Estimated average burden hours per response: 20.8

    N-PX: Filer Information

    Filer CIK
    0000200406 
    Filer CCC
    ********  
    Date of Report
    06/30/2025 
    Are you a Registered Management Investment Company or an Institutional Manager?
    Institutional Manager 
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Is this an electronic copy of an official filing submitted in paper format? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone Number
     
    E-mail Address
     

    Notification Information

    Notify via Filing Website only?Checkbox not checked

    N-PX: Cover Page

    Name and address of reporting person:

    Name of reporting person (For registered management investment companies, provide exact name of registrant as specified in charter)

    Johnson & Johnson 

    Street 1

    One Johnsons & Johnsons Plz 

    Street 2

     

    City

    New Brunswick 

    State/Country

    NEW JERSEY  

    Zip code and zip code extension or foreign postal code

    08933 

    Telephone number of reporting person, including area code:

    732-524-1476 

    Name and address of agent for service:

    Name of agent for service

     

    Street 1

     

    Street 2

     

    City

     

    State/Country

     

    Zip code and zip code extension or foreign postal code

     

    Reporting Period:Report for the year ended June 30, 2025 
    SEC Investment Company Act or Form 13F File Number:

    028-20072 

    CRD Number (if any):

     

    Other SEC File Number (if any):

     

    Legal Entity Identifier (if any):

     

    Report Type (check only one):

    Registered Management Investment Company.
    Radio button not checked Fund Voting Report (Check here if the registered management investment company held one or more securities it was entitled to vote.)
    Radio button not checked Fund Notice Report (Check here if the registered management investment company did not hold any securities it was entitled to vote.)
    Institutional Manager.
    Radio button not checked Institutional Manager Voting Report (Check here if all proxy votes of this reporting manager are reported in this report.)
    Radio button checked Institutional Manager Notice Report (Check here if no proxy votes are reported in this report and complete the notice report filing explanation section below)
    Notice report filing explanation:
    Radio button checked All proxy votes for which the manager exercised voting power are reported by other reporting persons
    Radio button not checked The reporting person did not exercise voting power for any reportable voting matter
    Radio button not checked The reporting person has a clearly disclosed policy of not voting and did not vote on any proxy voting matters
    Radio button not checked Institutional Manager Combination Report (Check here if a portion of the proxy votes for this reporting manager are reported in this report and a portion are reported by other reporting person(s).)
    Do you wish to provide explanatory information pursuant to Special Instruction B.4?: Radio button not checked Yes Radio button checked No
    Additional information:

     

    N-PX: Summary - Included Managers

    Number of Included Institutional Managers:

    0 

    Included Institutional Managers:NONE

    N-PX: Signature Block

    Reporting Person:

    Johnson & Johnson 

    By (Signature):

    Marc Larkins 

    By (Printed Signature):

    Marc Larkins  

    By (Title):

    Secretary 

    Date:

    08/26/2025 

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    7/23/2025Hold → Buy
    Erste Group
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    More analyst ratings

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

    NetworkNewsWire Editorial Coverage NEW YORK, Oct. 29, 2025 /PRNewswire/ -- The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral and intravenous treatments continue to face significant challenges, chief among them low bioavailability and inadequate tumor targeting. These factors often limit the success of these treatments in clinical settings. Breakthroughs in nanomedicine are now addressing these obstacles, with growing support from the U.S. Food and Drug Administration (FDA), along with other regulators for nanocarrier-based delivery technologies u

    10/29/25 8:30:00 AM ET
    $IOVA
    $JNJ
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

    The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVY™ demonstrated 72 weeks of sustained reduction in immunoglobulin G (IgG), sustained disease control and no new safety concerns IMAAVY™ is the only FcRn blocker for anti-AChR and anti-MuSK antibody positive adult and pediatric gMG patients aged 12 and older that has demonstrated sustained disease control SPRING HOUSE, Pa., Oct. 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced plans to initiate the first head-to-he

    10/29/25 8:05:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

    Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent efficacy and a favorable safety profile Results show 50.5% of adult psoriasis patients eligible for systemic therapy and 47.5% of dermatology providers would prefer oral treatment over topicals or injectables SPRING HOUSE, Pa., Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented

    10/27/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Johnson & Johnson from Equal Weight to Overweight and set a new price target of $212.00

    10/3/25 8:30:20 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Guggenheim with a new price target

    Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00

    9/23/25 8:13:07 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $JNJ
    SEC Filings

    View All

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Innovative Medicine, R&D Reed John C exercised 21,721 shares at a strike of $157.92 and sold $4,185,793 worth of shares (21,721 units at $192.71) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    10/20/25 7:13:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Morikis John G claimed ownership of 599 shares (SEC Form 3)

    3 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/15/25 4:36:54 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/11/25 5:52:29 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Johnson & Johnson

    10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

    10/22/25 4:04:17 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    10/14/25 7:22:58 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    9/8/25 7:55:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel

    10/14/25 6:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

    Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in

    10/14/25 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

    2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirm

    10/14/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care